Table 2 Distribution of median tCho, β-catenin and cyclin D1 concentrations in breast cancer patients (n = 20) based on the difference in their AJCC stage, menopausal status, and hormonal marker status.
Groups (n) | tCho (mmol/Kg) [Median (range)] | β-catenin (pg/ml) [Median (range)] | Cyclin D1 (ng/ml) [Median (range)] | ||
|---|---|---|---|---|---|
Cytosolic fraction | Nuclear fraction | Cytosolic fraction | Nuclear fraction | ||
AJCC Stage IIA (n = 11) | 5.7 (2.1–17.9) | 4.2 (1.8–7.5) | 8.9 (3.0–37.2) | 2.0 (1.0–2.0) | 2.1 (2.0–2.7) |
III (A + B) (n = 9) | 4.7 (3.5–9.6) | 5.6 (2.5–7.2) | 12.2 (4.3–35.7) | 2.0 (1.0–2.3) | 2.2 (2.0–2.6) |
Pre menopausal (n = 10) | 5.8 (3.5–8.6) | 5.1 (2.3–7.5) | 14.9 (3.1–39.7) | 2.0 (1.0–2.0) | 2.2 (2.0–2.6) |
Post menopausal (n = 10) | 4.5 (2.1–17.9) | 4.2 (1.8–6.7) | 6.7 (3.0–37.2) | 2.0 (1.0–2.3) | 2.1 (2.0–2.7) |
ER+ (n = 9) | 5.1 (3.5–9.6) | 4.2 (2.3–6.6) | 13.3 (3.7–37.2) | 2.0 (1.0–2.3) | 2.3 (2.0–2.7) |
ER− (n = 11) | 4.9 (2.1–17.9) | 4.5 (1.8–7.5) | 8.9 (3.0–35.7) | 2.0 (1.0–2.0) | 2.1 (2.0–2.6) |
PR+ (n = 10) | 5.3 (3.5–9.6) | 4.0 (2.3–5.8)* | 17.1 (3.7–39.7) | 2.0 (1.0–2.3) | 2.2 (2.0–2.7) |
PR− (n = 10) | 5.4 (2.1–17.9) | 5.1 (1.8–7.5)* | 11.1 (3.0–35.7) | 2.0 (1.0–2.0) | 2.1 (2.0–2.6) |
Her2neu+ (n = 9) | 4.7 (2.1–9.6) | 4.4 (2.5–7.5) | 16.5 (3.0–39.7) | 2.0 (1.0–2.3) | 2.2 (2.0–2.6) |
Her2neu− (n = 11) | 5.9 (3.5–17.9) | 5.6 (1.8–7.2) | 8.9 (3.1–37.2) | 2.0 (1.0–2.0) | 2.1 (2.0–2.7) |
